Table 1 Patient baseline characteristics
|  | Male N = 82 | Female N = 54 | p value |
|---|---|---|---|
Age (years) | 65.2 (6.8) | 63.6 (8.1) | 0.24 |
Race | |||
 White, % | 77(94) | 50 (93) |  |
 Black or African American, % | 3 (4) | 2 (4) | 0.84 |
 Others, % | 2 (2) | 2 (4) |  |
 Body mass index | 27.2 (4.9) | 27.2 (5.5) | 0.98 |
 Former smokers, % | 50 (61) | 26 (48) | 0.16 |
Post-bronchodilator FEV1 | |||
 Absolute (L) | 1.4 (0.5) | 1.2 (0.4) | 0.0036 |
 % predicted | 43.8 (15.5) | 51.3 (13.6) | 0.0043 |
 Post-bronchodilator FEV1/FVC ratio | 0.45 (0.1) | 0.52 (0.1) | 0.00024 |
 SGRQ-C score | 57.9 (17.3) | 57.1 (18.3) | 0.80 |
GOLD, % | |||
 Stage II | 31 (38) | 32 (59) |  |
 Stage III | 31 (38) | 18 (33) | 0.011 |
 Stage IV | 20 (24) | 4 (7) |  |
Patients with bronchodilator reversibility, % | 14 (17) | 6 (11) | 0.46 |
Patients with chronic bronchitis, % | 67 (82) | 41 (76) | 0.52 |
Patients with severe exacerbation in previous 12Â months, % | 26 (32) | 11 (20) | 0.17 |
Median blood eosinophil count (cells per μL) | 180 (130) | 175 (183) | 0.89 |
Median fibrinogen (g/L) | 3.8 (1.4) | 3.5 (0.9) | 0.037 |